Normally, blacklisting of a company has a finite life span, for a few years. But an “indefinite directive” is worse than blacklisting and illegal, the Supreme Court stated in its judgment in Daffodills Pharmaceuticals vs State of UP. In this case, the pharma company and 56 others bid for a contract to supply medicines to hospitals in the state in 2015. It was disqualified because one of its directors was under CBI lens for maintaining fictitious accounts for personal benefits. However, the company argued that he had resigned in 2012 and was no longer connected with it. It also argued before the Allahabad High Court that it was not given an opportunity to present its case. The high court dismissed the petition, upholding the ban. But the Supreme Court stated that the high court erred as the indefinite ban could not be legally sustained and the company was not heard before passing the drastic order.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)